Royalty Report: Medical, Diagnostic, Device – Collection: 28652


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Medical
  • Diagnostic
  • Device
  • Disease
  • Tissue

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28652

License Grant
Licensor hereby grants to Licensee an exclusive license under the Licensed Patents in the Field of Use to manufacture, have manufactured and to market, distribute and sell or otherwise, Licensed Products in the Territory.
License Property
Licensed Products means (i) units of consumable test strips for use in determination of blood or plasma coagulation, or (ii) any other articles falling within the scope of any of the claims of any of the Licensed Patents.
Field of Use
Field of Use  means  medical  devices  for  point of care  testing  or home testing for measuring plasma or blood coagulation.

IPSCIO Record ID: 5895

License Grant
The Licensor and Licensee together developed the prothrombin measurement device or 'PT Device'.
License Property
Prothrombin, a glycoprotein formed by and stored in the liver and present in the blood plasma that is converted to thrombin in the presence of thromboplastin and calcium ion during blood clotting. Also called factor II.
Field of Use
The prothrombin measurement device is used for the measurement of coagulation of blood in patients at risk of heart disease and stroke.

IPSCIO Record ID: 7331

License Grant
The Licensor has entered into a development contract and License Agreement for our prothrombin blood clotting measuring device with the  Scottish Licensee.

Under the Agreement with the Licensee, the Licensor will grant an exclusive, worldwide License for the use of technology to produce and market a prothrombin blood clotting measuring device.

License Property
Non-Invasive Blood Analyte Measurement Products

The development contract contributes over $2 million, over an 18-month period, and culminates in the delivery of the initial batch of units for market launch during calendar year 2005.

The prothrombin time test belongs to a group of blood tests that assess the clotting ability of blood. The test is also known as the pro time or PT test.

Field of Use
The monitor is the first in a series of applications that measures the content and characteristics of blood through the use of the Hall Effect, a well-known physics phenomenon that can be used to measure the change in magnetic fields – the spaces in which magnetic forces are detectable; created by magnetostrictive ultrasonic scalers to cause the tips of instruments such as ultrasonic scalers to vibrate.

Prothrombin is used by patients undergoing warfarin/coumadin anticoagulation therapy after a heart attack or stroke to ensure that drug levels are maintained at optimum levels.

Prothrombin blood clotting measuring device is a minimally-invasive, accurate and safe, characteristic measuring device for heart attack and stroke sufferers.

IPSCIO Record ID: 29416

License Grant
We entered into a settlement and mutual release agreement with the Company pursuant to which we received a non-exclusive, perpetual, non-transferable worldwide license to the patent rights in exchange for a product royalty based on sales.
License Property
Licensed Product(s) shall mean, on a country-by-country basis (i) Licensee’s INRatio™ test strip product(s), when made, used, sold, offered for sale or imported to a country for which there is a Valid Claim, and (ii) any other product(s) related to testing for blood coagulation, the manufacture, sale or use of would, but for the license granted herein, directly infringe a Valid Claim in the country of sale. For purposes of this definition of Licensed Product(s), “Valid Claim” means a claim of an issued and unexpired patent included within the Licensed Patents that has not been held invalid by a court of competent jurisdiction and that has not been disclaimed or admitted to be invalid or unenforceable through reissue or otherwise.
Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 203337

License Grant
Licensor grants a worldwide right and sublicense under the Patents to use the rTF in the Licensee Point of Care Product and to make, have made, sell or have sold the Point of Care Product.

Licensor will manufacture rTF for Licensee;  grant Licensee a license to sell the Point of Care Product; Licensor will have an option to distribute Licensees Point of Care Product and become an equity owner in Licensee.

License Property
Licensor holds patents and patent applications for various form of recombinant human tissue factor (“rTF”).

The HemoSense INRatio(tm) system consists of a meter and disposable test strips used to test Prothrombin Time (PT). The disposable test strips listed below incorporate the Licensor's recombinant tissue factor of this agreement.

Field of Use
This agreement is for the use of the product for the point of care or self test market.

The Point of Care Product shall mean that prothrombin time test currently being designed, and developed, by Licensee under the name of Comet for the point of care or self test market.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.